Regulatory roadmap: Class A IVD, European Union and Switzerland

15 phases · 60 steps · estimated duration 120 days

This is the order in which Normiq organises market access for the market "European Union and Switzerland" and the category "Class A IVD". Each step has a detailed guide — how to proceed, best practices, common mistakes, reference articles — reserved for Normiq accounts.

Not sure of the class? Check it rule by rule with the MDR and IVDR classification tool.

This pathway has 3 steps that the EU pathway of the same class does not. See the EU → Switzerland gap

  1. Phase 1

    IVD classification and strategy

    Classify the device under the rules of Annex VIII IVDR (classes A to D) and derive from it the conformity assessment procedure, and therefore the notified body's role.

    1. Classification according to IVDR

      required · 2 d

      Apply the IVDR classification rules

    2. Define the intended purpose

      required · 1 d

      The intended purpose of the device as claimed by the manufacturer. It drives the classification, the clinical evaluation and the content of the instructions for use.

  2. Phase 2

    Economic operators and responsibilities

    Who answers for what along the supply chain: authorised representative, person responsible for regulatory compliance, financial coverage, importer and distributor.

    1. Appoint an authorised representative established in the Union

      required · 60 d

      Mandatory for any manufacturer without a place of business in the Union — therefore for every Swiss manufacturer targeting the European market.

    2. Appoint the person responsible for regulatory compliance

      required · 30 d

      Every manufacturer must have at least one person with the requisite expertise available. The authorised representative must have their own.

    3. Establish financial coverage for liability

      required · 20 d

      Measures proportionate to the risk class, type of device and size of the enterprise, without prejudice to the product liability directive.

    4. Frame the obligations of importers and distributors

      required · 45 d

      Pre-market checks, identification particulars, complaints register, storage conditions — and the cases where they take on your obligations as manufacturer.

  3. Phase 3

    IVD technical documentation

    1. Description du device IVD

      required · 5 d
    2. Risk management ISO 14971

      required · 10 d

      A continuous iterative process across the whole lifecycle, not an analysis run once. The Regulation sets its six obligations and the priority order of control measures; ISO 14971 supplies the method.

    3. Studies de performance

      required · 25 d

      Studies analytiques et cliniques de performance

    4. Instructions for Use IVD

      required · 3 d
  4. Phase 4

    Quality management system

    The obligation of Article 10(9): a documented system, proportionate to the risk class, covering thirteen aspects — from the strategy for regulatory compliance to product improvement. ISO 13485 is the route to presumption of conformity, not the source of the obligation.

    1. Measure the gap between what exists and the quality system requirements

      required · 120 d

      Start from the thirteen aspects of Article 10(9) and record, for each, what exists, what is missing, and what exists without being documented.

    2. Write the system’s procedures and records

      required · 120 d

      Write what the gap analysis showed to be absent or undocumented. The number of procedures depends on the scope, not on a scale.

    3. Draw up the list of applicable general safety and performance requirements

      required · 30 d

      Aspect (b): identify, requirement by requirement of Annex I, those that apply to the device, and the solution adopted for each.

    4. Organise management responsibility and management review

      required · 15 d

      Aspect (c): top management owns the system, sets its objectives, periodically reviews its effectiveness and decides on resources.

    5. Manage resources, suppliers and sub-contractors

      required · 45 d

      Aspect (d): competence of personnel, infrastructure and work environment, and above all selection, evaluation and monitoring of those who produce for you.

    6. Control design and development

      required · 90 d

      Aspect (g), design side: plan, set the inputs, produce the outputs, review, verify, validate, transfer, and control every change.

    7. Control production and service provision

      required · 60 d

      Aspect (g), production side: controlled conditions, validation of processes whose output cannot be verified, cleanliness, installation, servicing, traceability.

    8. Establish the file for each device type

      required · 20 d

      The file that, for each type or family of devices, gathers or references the specifications, processes, labelling, measurement and traceability. It is the hinge between the quality system and the technical documentation.

    9. Verify UDI assignments and the consistency of registration information

      required · 10 d

      Aspect (h): the quality system must verify that every device has received its UDI and that what you declared in the database matches the device as sold.

    10. Manage corrective and preventive actions and verify their effectiveness

      required · 30 d

      Aspect (l): eliminate the cause of an actual or potential non-conformity, then prove the action worked. Verification of effectiveness is written into the regulation.

    11. Control nonconforming product, measure, analyse data and improve

      required · 30 d

      Aspect (m): what is not conforming is identified and held, what is produced is measured, data is analysed and the product improves. The loop that keeps the system alive.

    12. Internal audit of the quality management system

      required · 45 d

      Periodic, documented verification that the quality system is applied and effective. It is the first document a notified body asks for.

  5. Phase 5

    Conformity assessment specifics

    The additional steps triggered by what the device does, not by its class alone: expert panel, reference laboratory, consultation of the EMA.

    1. Position the device against harmonised standards and common specifications

      required · 30 d

      The two routes that confer presumption of conformity, and what must be written to depart from them.

    2. Handle the case of self-testing and near-patient testing

      recommended · 60 d

      A self-test involves a notified body whatever its class. This is the rule that classification alone does not reveal.

  6. Phase 6

    Information supplied with the device

    Languages required, unique identifier and its carrier, public summary of characteristics, implant card.

    1. Establish the language matrix by Member State

      required · 45 d

      The language of labelling and instructions is set by each Member State of marketing, not by the regulation.

    2. Put the unique device identification system in place

      required · 60 d

      Basic UDI-DI, UDI-DI, UDI-PI, carrier on the label and all packaging levels, upload before placing on the market.

    3. Check the UDI carrier deadline (IVD)

      required · 15 d

      IVD dates differ from those for medical devices: 2023 for class D, 2025 for classes B and C, 2027 for class A.

  7. Phase 7

    EU Declaration of Conformity et CE marking

    1. Draft the EU Declaration of Conformity

      required · 21 d

      Sign the declaration attesting conformity with the MDR

    2. Affix CE marking

      required · 1 d

      Affix the CE marking visibly and indelibly on the device

  8. Phase 8

    EUDAMED registration

    Register the operator (SRN) and then each device in EUDAMED, four of whose modules have been mandatory since 28 May 2026.

    1. Operator registration in EUDAMED

      required · 1 d

      Obtain the single registration number (SRN) of the manufacturer and, where applicable, of the authorised representative and the importer, before any placing on the market.

    2. Assignment of the unique device identifier (UDI)

      required · 45 d

      Assign the Basic UDI-DI and the UDI-DIs through an issuing entity designated by the Commission: GS1, HIBCC, ICCBBA or IFA.

    3. Device registration in EUDAMED

      required · 2 d

      Enter the device data in the UDI/Devices module: before placing on the market, or by 28 November 2026 at the latest for a device already marketed.

  9. Phase 9

    Swiss formalities

    UDI, operator registration (CHRN) and device registration in swissdamed, all before placing on the market.

    1. Appoint a Swiss authorised representative

      required · 14 d

      A manufacturer with no registered office in Switzerland may place its devices on the Swiss market only after appointing, in writing, an authorised representative established in Switzerland.

    2. Register the economic operator with Swissmedic

      required · 14 d

      To be done before first placing on the market, since 1 July 2026. Swissmedic verifies the data and assigns the CHRN; it is not an authorisation.

  10. Phase 10

    Post-Market Surveillance (PMS)

    1. IVD PMS plan

      required · 4 d
    2. IVD vigilance system

      required · 4 d
  11. Phase 11

    Vigilance and post-market surveillance

    What starts once the device is on the market: incident reporting, trends, corrective actions, clinical follow-up, periodic reports.

    1. Meet the deadlines for reporting serious incidents

      required · 30 d

      Three distinct deadlines: 15 days as a rule, 10 days in the event of death, 2 days in the event of a serious public health threat.

    2. Put trend reporting in place

      required · 30 d

      An obligation distinct from vigilance: it covers NON-serious incidents and expected side effects.

    3. Organise field safety corrective actions and safety notices

      required · 30 d

      Recall, withdrawal, modification, update: the action is notified, and the safety notice reaches users in their language.

    4. Choose between surveillance report and periodic report (IVD)

      required · 30 d

      Classes A and B: a surveillance report. Classes C and D: an annual periodic safety update report.

  12. Phase 12

    Performance evaluation and performance studies

    The clinical evidence for an IVD: scientific validity, analytical performance, clinical performance — and the studies governed by Articles 57 to 77 where they are required.

    1. Establish the performance evaluation and its report

      required · 120 d

      The three pillars of the evidence: scientific validity, analytical performance, clinical performance. Mandatory for all classes.

    2. Determine whether a performance study falls under Articles 57 to 77

      required · 15 d

      Not every study triggers the heavy procedure. Four situations do.

    3. Obtain the ethics committee opinion

      required · 60 d

      A condition for starting in every case, including those where no authorisation is required.

    4. Submit the application and follow the validation

      required · 45 d

      Submission through the Article 69 electronic system, a single Union-wide identification number, completeness response within 10 days.

    5. Manage substantial modifications

      required · 45 d

      Notification within one week, and implementation no earlier than 38 days later.

    6. Record and report adverse events

      required · 10 d

      Four categories to record in full, three to report without delay. An incomplete initial report is permitted.

    7. Declare the end of the study and publish the report

      required · 90 d

      15 days for a temporary halt or early termination, 24 hours where safety is the reason.

  13. Phase 13

    Ongoing obligations and compliance checks

    Obligations that do not end at CE marking: unique identification, traceability, notice of supply interruption, and checks against deadlines that have already passed.

    1. Give notice of interruption or discontinuation of supply

      required · 15 d

      Obligation introduced in 2024: give at least six months’ notice where an interruption could cause serious harm.

    2. Ensure traceability of economic operators

      required · 20 d

      Be able to name, at the authority’s request, every operator upstream and downstream, and in Switzerland the health institutions supplied.

    3. Switzerland — obtain an export certificate from Swissmedic

      required · 30 d

      Swissmedic issues, on request, the certificates required by third countries, to manufacturers or authorised representatives with their seat in Switzerland.

  14. Phase 14

    Obligations depending on the distribution model

    To check once: procedure packs, reprocessing, custom-made, distance sales, products without a medical purpose, in-house devices, free sale certificate.

    1. Handle the case of IVDs manufactured and used in-house

      recommended · 30 d

      An exemption for health institutions, subject to strict cumulative conditions — including proof that no equivalent exists on the market.

    2. Handle the case of distance sales

      recommended · 20 d

      A device offered online must be compliant — and so must a device never placed on the market but used for a commercial service.

    3. Obtain a free sale certificate for export

      recommended · 30 d

      Issued by the Member State where the manufacturer has its registered place of business, on request, for export purposes.

    4. Electrical device: the RoHS Directive applies on top of the MDR or IVDR

      recommended · 30 d

      An electrical or electronic device also falls under Directive 2011/65/EU. Ten substances are restricted, and the limits are assessed material by material.

    5. Apply for or renew a RoHS exemption

      recommended · 60 d

      Where a restricted substance remains indispensable, Article 5 opens an exemption application — to be filed well ahead of the expiry date.

  15. Phase 15

    Transitional regime (devices under the old directives)

    Applies if your device is still covered by a certificate or declaration of conformity drawn up under the old directives. Determines the date on which you lose the right to place it on the market.

    1. Determine whether the device falls under the transitional regime

      required · 5 d

      Three situations open the door to the transitional regime. Outside them, the device must comply with the MDR or IVDR now.

    2. Identify the end date of the transitional regime

      required · 3 d

      The date after which the device can no longer be placed on the market or put into service without certification under the new regulation. It depends on the risk class.

    3. Check the conditions for keeping the benefit of the transition

      required · 10 d

      The transitional regime is conditional. Four substantive conditions, plus dated milestones whose breach ends the right to place the device on the market.

    4. Apply the new regulation’s obligations during the transition

      required · 30 d

      The transition does not suspend everything. Four blocks of obligations under the new regulation apply now, in place of the old directives’ equivalents.

    5. Organise the transfer of surveillance to the new notified body

      required · 45 d

      During the transition, responsibility for surveillance changes hands. The arrangements must be set out in writing between the parties.

The detailed guide for each step — how to proceed, best practices, common mistakes — is reserved for Normiq accounts.

Track these deadlines device by device

Normiq places every deadline in your device's roadmap, with the steps that lead to it. Free 7-day trial.

Open this roadmap in Normiq

Other pathways on this market